P
Panagiotis A. Konstantinopoulos
Researcher at Harvard University
Publications - 239
Citations - 12541
Panagiotis A. Konstantinopoulos is an academic researcher from Harvard University. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 49, co-authored 201 publications receiving 9202 citations. Previous affiliations of Panagiotis A. Konstantinopoulos include Tufts University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri,Elsa Callen,Xia Ding,Ewa Gogola,Alexandra A. Duarte,Ji-Eun Lee,Nancy Wong,Vanessa Lafarga,Jennifer A. Calvo,Nicholas J. Panzarino,Sam John,Amanda Day,Anna Vidal Crespo,Binghui Shen,Linda M. Starnes,Julian R. de Ruiter,Jeremy A. Daniel,Panagiotis A. Konstantinopoulos,David Cortez,Sharon B. Cantor,Oscar Fernandez-Capetillo,Kai Ge,Jos Jonkers,Sven Rottenberg,Sven Rottenberg,Shyam K. Sharan,André Nussenzweig +26 more
TL;DR: It is shown that loss of the MLL3/4 complex protein, PTIP, protects Brca1/2- deficient cells from DNA damage and rescues the lethality of Brca2-deficient embryonic stem cells, but PTIP deficiency does not restore homologous recombination activity at double-strand breaks.
Journal ArticleDOI
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi,Jessica Liu,Ravindra Amunugama,Ildiko Hajdu,Benjamin Primack,Mark I.R. Petalcorin,Kevin W O'Connor,Panagiotis A. Konstantinopoulos,Stephen J. Elledge,Simon J. Boulton,Timur Yusufzai,Alan D. D'Andrea +11 more
TL;DR: The results reveal a synthetic lethal relationship between the HR pathway and Polθ-mediated repair in EOCs, and identifyPolθ as a novel druggable target for cancer therapy.
Journal ArticleDOI
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
TL;DR: The genotypic and phenotypic characteristics of HR-deficient EOCs are described, current and emerging approaches for targeting these tumors are discussed, and present challenges associated with these approaches, focusing on development and overcoming resistance.
Journal ArticleDOI
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt,Sachet A. Shukla,Lynette M. Sholl,Lauren L. Ritterhouse,Jaclyn C Watkins,Scott J. Rodig,Elizabeth H. Stover,Kyle C. Strickland,Alan D. D'Andrea,Catherine J. Wu,Catherine J. Wu,Ursula A. Matulonis,Panagiotis A. Konstantinopoulos +12 more
TL;DR: Polymerase e-mutated and MSI ECs are associated with high neoantigen loads and number of TILs, which is counterbalanced by overexpression of PD-1 and PD-L1, which may be excellent candidates forPD-1-targeted immunotherapies.
Journal ArticleDOI
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C. Strickland,Brooke E. Howitt,Sachet A. Shukla,Scott J. Rodig,Lauren L. Ritterhouse,Joyce F. Liu,Judy Garber,Dipanjan Chowdhury,Catherine J. Wu,Catherine J. Wu,Alan D. D'Andrea,Ursula A. Matulonis,Panagiotis A. Konstantinopoulos +12 more
TL;DR: Findings support a link between BRCA1/2-mutation status, immunogenicity and survival, and suggest that BRC a2-mutated HGSOCs may be more sensitive to PD-1/PD-L1 inhibitors compared to HR-proficient H GSOCs.